Patients with chronic myelogenous leukemia have at (9; 22)(q34; q11. 2) or variant
translocation that results in a BCR-ABL fusion gene. BCR-ABL detection by quantitative …

Abstract The Philadelphia (Ph; BCR‑ABL) chromosome originates from a translocation event
between chromosomes 9 and 22, and results in the BCR‑ABL fusion gene. In chronic …

Myoepithelial neoplasms (MN) are rare and not well-circumstanced entities displaying a
heterogeneous spectrum of genetic abnormalities, including EWSR1, FUS and PLAG1 …

Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated
tyrosine kinase, the Bcr-Abl oncoprotein. An inhibitor of this tyrosine kinase, imatinib …

Currently, all identified fusion oncogenes are found in rare tumor forms, and most of them
only in specific tumor types. Some fusion oncogenes are frequent in healthy individuals …

Background t (9; 22) is a balanced translocation, and the chromosome 22 breakpoints
(Philadelphia chromosome–Ph+) determine formation of different fusion genes that are …

Bach2 is a lymphoid-specific transcription factor with a prominent role in B-cell development
and apoptosis-induction in response to oxidative stress. We previously showed that Bach2 is …

The development of imatinib has resulted in sustained hematologic and cytogenetic
remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy …

JAK2 (Janus kinase 2) V617F, CALR (Calreticulin) exon 9, and MPL (receptor for
thrombopoietin) exon 10 mutations are associated with the vast majority of Ph-negative …

BCR-ABL, a constitutively active tyrosine kinase, causes chronic myeloid leukaemia (CML).
Rational development of drugs targeting BCR-ABL has significantly improved the treatment …